SCHEMBL288684

SCHEMBL288684

CC(N)(N)CCCC(=O)O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.48
SLC22A6 Q4U2R8 2/20 0.48
TSHR P16473 7/20 0.46
HDAC11 Q96DB2 6/20 0.46
KMT2A Q03164 4/20 0.46
THRB P10828 3/20 0.46
CYP1A2 P05177 2/20 0.46
BLM P54132 2/20 0.46
NPSR1 Q6W5P4 2/20 0.46
GABRR3 A8MPY1 1/20 0.46
GABRP O00591 1/20 0.46
GABRD O14764 1/20 0.46
HDAC3 O15379 1/20 0.46
GABBR2 O75899 1/20 0.46
GABRA1 P14867 1/20 0.46
GABRB1 P18505 1/20 0.46
GABRG2 P18507 1/20 0.46
GABRR1 P24046 1/20 0.46
GABRB3 P28472 1/20 0.46
GABRR2 P28476 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL27328296 0.98 BLM (0.46) LMNASLC22A6TSHRHDAC11KMT2A
SCHEMBL27468299 0.91 TSHR (0.55) LMNASLC22A6TSHRHDAC11KMT2A
SCHEMBL2227903 0.85 LMNA (0.48) LMNASLC22A6TSHRHDAC11KMT2A
SCHEMBL2825360 0.84
Hydrochloric Acid SCHEMBL27951470 0.83 BLM (0.46) LMNASLC22A6TSHRHDAC11KMT2A
SCHEMBL28000197 0.82 KMT2A (0.35) LMNAKMT2ATHRBCYP1A2BLM
Adipic Acid SCHEMBL11074254 0.81 LMNA (0.65) LMNASLC22A6TSHRHDAC11KMT2A
Adipic Acid SCHEMBL11077556 0.81 LMNA (0.65) LMNASLC22A6TSHRHDAC11KMT2A
SCHEMBL9003618 0.81 ARG1 (0.57) LMNASLC22A6TSHRHDAC11KMT2A
SCHEMBL1300781 0.81 ARG1 (0.57) LMNASLC22A6TSHRHDAC11KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 140 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12527880-B2 Cyanine-based telodendrimers and uses for treating cancer THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2026-01-20 US claimed
US-20250000811-A1 TELODENDRIMER NANOCARRIERS FOR MONOMERIC AMPHOTERICIN B DELIVERY UNIV NEW YORK STATE RES FOUND (US) 2025-01-02 US claimed
US-11649326-B2 Functional, segregated, charged telodendrimers and nanocarriers and methods of making and using same THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) 2023-05-16 US claimed
US-20230076792-A1 SEQUENTIAL TARGETING IN CROSSLINKING NANO-THERANOSTICS FOR TREATING BRAIN TUMORS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2023-03-09 US claimed
CN-115551917-A Sequential targeting of cross-linked nanotherapeutics for the treatment of brain tumors 加利福尼亚大学董事会 2022-12-30 CN claimed
US-11406714-B2 Telodendrimers and nanocarriers and methods of using same THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) 2022-08-09 US claimed
EP-3347053-B1 FUNCTIONAL, SEGREGATED, CHARGED TELODENDRIMERS AND NANOCARRIERS AND METHODS OF MAKING AND USING SAME THE RESEARCH FOUNDATION FOR STATE UNIV OF NEW YORK (US) 2022-05-25 EP claimed
US-11219692-B2 Porphyrin modified telodendrimers THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2022-01-11 US claimed
US-20210346518-A1 CYANINE-BASED TELODENDRIMERS AND USES FOR TREATING CANCER THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2021-11-11 US claimed
CN-113330056-A Cyanine-based terminal dendritic copolymers and their use for the treatment of cancer 加利福尼亚大学董事会 2021-08-31 CN claimed
US-20160038605-A1 PORPHYRIN MODIFIED TELODENDRIMERS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2016-02-11 US claimed
EP-2931290-A1 PORPHYRIN MODIFIED TELODENDRIMERS The Regents of The University of California (US) 2015-10-21 EP claimed
WO-2015027054-A2 TELODENDRIMERS AND NANOCARRIERS AND METHODS OF USING SAME THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) 2015-02-26 WO claimed
US-20150056139-A1 TELODENDRIMERS AND NANOCARRIERS AND METHODS OF USING SAME NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-02-26 US claimed
WO-2014093675-A1 PORPHYRIN MODIFIED TELODENDRIMERS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2014-06-19 WO claimed
US-20140161719-A1 PORPHYRIN MODIFIED TELODENDRIMERS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2014-06-12 US claimed
EP-2707419-A2 REVERSIBLY CROSSLINKED MICELLE SYSTEMS The Regents of the University of California (US) 2014-03-19 EP claimed
WO-2012158622-A2 REVERSIBLY CROSSLINKED MICELLE SYSTEMS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2012-11-22 WO claimed
EP-2344134-A2 NANOCARRIERS FOR DRUG DELIVERY The Regents of the University of California (US) 2011-07-20 EP claimed
WO-2010039496-A2 NANOCARRIERS FOR DRUG DELIVERY THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2010-04-08 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210346518-A1 CYANINE-BASED TELODENDRIMERS AND USES FOR TREATING CANCER TYR, LGALS3, ABL1 LMNA 2523/4885SLC22A6 2253/4885TSHR 1907/4885
US-20140161719-A1 PORPHYRIN MODIFIED TELODENDRIMERS CETP, NR1H4, ABCB4 LMNA 2451/4885SLC22A6 379/4885TSHR 647/4885
US-12527880-B2 Cyanine-based telodendrimers and uses for treating cancer TUBB1, CA13, YWHAZ LMNA 4046/4885SLC22A6 856/4885TSHR 1069/4885
US-20230076792-A1 SEQUENTIAL TARGETING IN CROSSLINKING NANO-THERANOSTICS FOR TREATING BRAIN TUMORS TIE1, CA12, CA13 LMNA 3488/4885SLC22A6 969/4885TSHR 2376/4885
US-11406714-B2 Telodendrimers and nanocarriers and methods of using same TTI2, MTCL3, HTT LMNA 1494/4885SLC22A6 2701/4885TSHR 669/4885
US-20150056139-A1 TELODENDRIMERS AND NANOCARRIERS AND METHODS OF USING SAME TTI2, MTCL3, HTT LMNA 1494/4885SLC22A6 2701/4885TSHR 669/4885
US-20160038605-A1 PORPHYRIN MODIFIED TELODENDRIMERS CETP, NR1H4, ABCB4 LMNA 2451/4885SLC22A6 379/4885TSHR 647/4885
US-11649326-B2 Functional, segregated, charged telodendrimers and nanocarriers and methods of making and using same TSPO, TBCA, TTI2 LMNA 3051/4885SLC22A6 748/4885TSHR 917/4885
US-11219692-B2 Porphyrin modified telodendrimers CETP, NR1H4, ABCB4 LMNA 2451/4885SLC22A6 379/4885TSHR 647/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.